Gastric Cancer

Findings from the phase 1b/2 MORPHEUS study indicated that patients with gastric and gastroesophageal junction cancer experienced limited responses to second-line linagliptin plus atezlolizumab.

Data from patients with gastric or gastroesophageal junction cancers who were treated with nivolumab showed that effects in the genomic pathways of the gut microbiome may be significantly associated with survival.

Research suggests that perioperative S-1 plus oxaliplatin in patients with gastric cancer who have had a D2 gastrectomy yields a clinically significant improvement over adjuvant capecitabine plus oxaliplatin.

Recent data indicated that the combination of neoadjuvant docetaxel, oxaliplatin, and S-1 followed by surgery and adjuvant S-1 was effective and tolerable in a population of Korean patients who had locally advanced gastric cancer.

The pharmaceutical company plans to voluntarily withdraw the accelerated approval indication for pembrolizumab in the third line setting for patients with gastric cancer within the coming months.

The agency approved nivolumab in combination with certain types of chemotherapy for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma, making it the first approved first-line immunotherapy for this patient population.

Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr virus–related, microsatellite instability–high/mismatch repair deficient or PD-L1–positive advanced gastric cancer.

Trastuzumab deruxtecan has not only demonstrated efficacy as a potential anti-HER2 therapeutic option for patients with HER2-amplified gastric cancers, but has also shown promise in those with HER2 moderate-, low-, and non-expressing disease.

Incidence of early-onset gastric cancer has steadily increased in the US, now comprising >30% of new gastric cancer cases today, causing researchers to try and discover what makes this disease type unique.

A combination of trifluridine and tipiracil showed some gains in overall survival for patients with metastatic gastric cancer or gastroesophageal junction cancer.

TAS-102 improved overall survival, compared with placebo, in patients with metastatic gastric or gastroesophageal junction (GEJ) cancer.

Laparoscopy-assisted distal gastrectomy offered better short-term, post-surgical outcomes for patients with locally advanced gastric cancer who were undergoing neoadjuvant chemotherapy. 

Patients responded relatively well to the phase I trial testing a new treatment for several malignancies, including gastric and gastroesophageal junction adenocarcinomas.

A new study found an upward trend over the last 12 years of cases of gastrointestinal cancer in young patients in Latin America.

Dr. Wilson discusses a chemopreventive drug that may help prevent gastric cancer by acting directly on H. pylori.

Researchers tested the novel oral fluoropyrimidine derivative S-1 plus oxaliplatin vs S-1 plus cisplatin in patients with diffuse-type or mixed-type advanced gastric adenocarcinoma.

Select patients with advanced gastric or gastroesophageal junction cancer may benefit from initial therapy with pembrolizumab, according to the KEYNOTE-062 trial.

Cancer Network spoke with Dr. Shaila Merchant about the difficulty in determining and linking the many disparities in gastric cancer and how genetic research can help.

Researchers found that adding andecaliximab to treatment for gastric cancer may benefit older patients.

As part of our coverage of the 2018 GI Cancers Symposium, we discussed the role of locoregional therapies for patients with metastatic esophageal and gastric cancers.

First-line ramucirumab in combination with chemotherapy significantly improved progression-free survival in patients with metastatic gastric or gastroesophageal junction adenocarcinoma, according to results of the RAINFALL trial.

Undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) resulted in improved overall survival compared with resection alone for patients with gastric cancer with peritoneal carcinomatosis, according to data presented at the 2018 Gastrointestinal Cancers Symposium.

The FDA approved a biosimilar for trastuzumab, Ogivri, for the treatment of patients with HER2-positive breast and stomach cancer.

Do you know how many men and women are estimated to be diagnosed with gastric cancer this year? How about some of the known risk factors for this disease? Test your knowledge in our latest quiz.

The combination of olaparib plus paclitaxel failed to significantly improve overall survival compared with placebo plus paclitaxel in Asian patients with advanced gastric cancer, according to the phase III results of the GOLD study.